Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT). A Randomized, Double-Blind, Placebo-Controlled Trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F11%3AN0000001" target="_blank" >RIV/00098892:_____/11:N0000001 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/11:00055476 RIV/61988987:17110/11:A12014HT RIV/61989592:15110/11:73598555

Result on the web

<a href="https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.111.169961" target="_blank" >https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.111.169961</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.169961" target="_blank" >10.1161/HYPERTENSIONAHA.111.169961</a>

Result language

angličtina

Original language name

Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT). A Randomized, Double-Blind, Placebo-Controlled Trial

Original language description

There is currently limited data on which drug should be used to improve blood pressure (BP) control in patients with resistant hypertension. This study was designed to assess the effect of the addition of 25 mg of spironolactone on BP in patients with resistant arterial hypertension. Patients with office systolic BP >140 mm Hg or diastolic BP >90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicenter trial. One hundred seventeen patients were randomly assigned to receive spironolactone (n=59) or a placebo (n=58) as an add-on to their antihypertensive medication, by the method of simple randomization. Analyses were done with 111 patients (55 in the spironolactone and 56 in the placebo groups). At 8 weeks, the primary end points, a difference in mean fall of BP on daytime ambulatory BP monitoring (ABPM), between the groups was −5.4 mm Hg (95%CI −10.0; −0.8) for systolic BP (P=0.024) and −1.0 mm Hg (95% CI −4.0; 2.0) for diastolic BP (P=0.358). The APBM nighttime systolic, 24-hour ABPM systolic, and office systolic BP values were significantly decreased by spironolactone (difference of −8.6, −6.6, and −6.5 mm Hg; P=0.011, 0.004, and 0.011), whereas the fall of the respective diastolic BP values was not significant (−3.0, −1.0, and −2.5 mm Hg; P=0.079, 0.405, and 0.079). The adverse events in both groups were comparable. In conclusion, spironolactone is an effective drug for lowering systolic BP in patients with resistant arterial hypertension.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2011

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Hypertension

ISSN

0194-911X

e-ISSN

1524-4563

Volume of the periodical

57

Issue of the periodical within the volume

6

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

1069-1075

UT code for WoS article

000290710800017

EID of the result in the Scopus database

2-s2.0-79956349197